Written question asked by Daisy Cooper (Liberal Democrat) on Tuesday, 7 November 2023, in the House of Commons. It was due for an answer on Monday, 13 November 2023 (named day). It was answered by Will Quince (Conservative) on Monday, 13 November 2023 on behalf of the Department of Health and Social Care.
Sotrovimab
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of anti-viral drug Sotrovimab for immunocompromised patients.
- Answer
-
The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.
The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.
Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.
Secondary information
- Type
- Written question
- Reference
- 501
- Session
- 2023-24
- Grouped for answer
- Yes
- Subjects
- Immunosuppression Sotrovimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-11-18 14:09:29 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/501
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/501
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/501